Clinical Scorecard: Case Study: Autoinflammatory Syndrome Associated with TRNT1 in a Patient Diagnosed with Primary Ciliary Dyskinesia

At a Glance

Key Highlights

• First documented case of homozygosity for the c.1246A>G variant in the TRNT1 gene
• Patient exhibited milder clinical phenotype compared to previously reported cases
• Etanercept effectively controlled autoinflammatory manifestations
• No adverse safety events observed during treatment
• Importance of considering autoinflammatory disease in patients with mild or delayed symptoms

Guideline-Based Recommendations

Diagnosis

• Genetic testing for pathogenic mutations in the TRNT1 gene in patients with recurrent fever and arthralgia

Management

• Initiate treatment with Etanercept for autoinflammatory manifestations

Monitoring & Follow-up

• Monitor inflammatory markers and clinical symptoms during treatment

Risks

• Elevated risk of infectious pulmonary complications due to concurrent primary ciliary dyskinesia

Patient & Prescribing Data

Young adults with primary ciliary dyskinesia and TRNT1-related autoinflammatory syndrome

Etanercept started at a reduced dosing schedule due to risk of respiratory exacerbations, later intensified for better control

Clinical Best Practices

• Consider autoinflammatory syndromes in differential diagnosis for patients with recurrent fever and arthralgia
• Utilize genetic testing to confirm TRNT1 mutations
• Adjust treatment regimens based on individual patient response and safety considerations

Related Resources & Content

• Source Article